The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary (2015)
Chapter: Appendix B: Workshop Agenda
June 8, 2015
| 7:30 am | Registration |
|
8:00 am |
Welcome from the National Cancer Policy Forum |
| Sharyl Nass, Institute of Medicine | |
| Director, National Cancer Policy Forum | |
|
Overview of the Workshop |
|
| Michael Kastan, Duke Cancer Institute | |
| Planning Committee Chair | |
|
8:15 am |
Session 1: Overview and Value of Trials That Include |
| Pets in Translational Cancer Research | |
| Moderator: Michael Kastan, Duke Cancer Institute | |
|
Overview of current challenges and opportunities in oncology drug development |
|
| Lee Helman, National Cancer Institute | |
|
Strengths and limitations of traditional preclinical models |
|
| Beverly Teicher, National Cancer Institute |
|
Advantages and experiences with trials that include animal patients |
|
| Chand Khanna, National Cancer Institute | |
|
Group Discussion |
|
|
10:10 am |
Break |
|
10:20 am |
Session 2: Canine Tumor Biology and Genomics Informing Cancer Drug Development |
| Moderator: Deborah Knapp, Purdue University | |
|
The current state of canine tumor genetics and scientific limitations |
|
| Heidi Parker, National Human Genome Research Institute | |
|
Use and availability of canine cancer tissue banks in translational research |
|
| Matthew Breen, North Carolina State University | |
|
Genomic resources for canine cancer research |
|
| Jessica Alföldi, Broad Institute of the Massachusetts Institute of Technology and Harvard University | |
|
Biology and informatics needs |
|
| Jeff Trent, Translational Genomics Research Institute | |
|
Group Discussion |
|
|
12:15 pm |
Lunch Break |
|
1:00 pm |
Session 3: Effectively Integrating Biomarkers into Study Designs |
| Moderator: Carl Barrett, AstraZeneca | |
|
Opportunities for preclinical evaluation of novel therapies |
|
| Timothy Fan, University of Illinois at Urbana-Champaign |
|
Pharmacokinetic (PK) assessment |
|
| Dan Gustafson, Colorado State University | |
|
Pharmacodynamics (PDs) and potential predictive biomarkers |
|
| Doug Thamm, Colorado State University | |
|
Group Discussion |
|
|
2:30 pm |
Session 4: Effectively Integrating Imaging Technologies into Study Designs |
| Moderator: Peter Choyke, National Cancer Institute | |
|
Role of trials that include pets in the development of new imaging modalities |
|
| Peter Choyke, National Cancer Institute | |
|
Role of magnetic resonance imaging in studying tumor physiology: A clinical perspective |
|
| Mark Dewhirst, Duke University | |
|
Group Discussion |
|
|
3:30 pm |
Break |
|
3:45 pm |
Session 5: Mechanisms for Comparative Oncology Trials |
| Moderator: Lou DeGennaro, Leukemia & Lymphoma Society | |
|
Single-institution studies |
|
| Cheryl London, Ohio State University | |
|
Multi-institution studies |
|
| Amy LeBlanc, National Cancer Institute | |
|
Group Discussion |
|
|
4:45 pm |
Wrap Up Day 1 |
June 9, 2015
|
7:30 am |
Registration |
|
8:00 am |
Session 6: Addressing the Needs of Pet Animals and Their Owners |
| Moderator: Michael Lairmore, University of California, Davis | |
|
Trial design and appropriate oversight |
|
| David Vail, University of Wisconsin–Madison | |
|
Best practices for conduct of clinical trials for animal patients |
|
| Rod Page, Colorado State University | |
| Patricia Olson, Independent Advisor on Animal Health and Welfare | |
|
Group Discussion |
|
|
9:45 am |
Break |
|
10:00 am |
Session 7: The Status of Comparative Oncology in Drug Development |
| Moderator: Perry Nisen, Sanford-Burnham Medical Discovery Institute | |
|
Panelists: |
|
| Anne Keane, Achaogen | |
| John Leighton, Food and Drug Administration | |
| Wendy Levin, Fate Therapeutics | |
| Daniel Tumas, Gilead Sciences, Inc. | |
|
Group Discussion |
|
|
11:30 am |
Workshop Wrap Up |
| Deborah Knapp, Purdue University | |
| Len Lichtenfeld, American Cancer Society | |
|
12:00 pm |
Adjourn |
